Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The purpose of this study is to evaluate the relative bioavailability of the test formulation of Zidovudine 300 mg tablets with an already marketed reference formulation RETROVIR ® 300 mg tablets (GlaxoSmithKline), under fasted conditions in healthy male and female adult subjects.
Epistemonikos ID: c6fe87df832c2ab555869177226d41691f3a827b
First added on: May 05, 2024